NovaBay Pharmaceuticals, Inc.NBYEarnings & Financial Report
NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on products for eye care. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis. and NeutroPhase, used in treatment of Necrotizing Fasciitis
Revenue
$2.5M
Gross Profit
$1.7M
Operating Profit
$-698.0K
Net Profit
$-1.8M
Gross Margin
67.0%
Operating Margin
-28.1%
Net Margin
-70.8%
YoY Growth
-35.2%
EPS
$-13.11
NovaBay Pharmaceuticals, Inc. Q3 FY2023 Financial Summary
NovaBay Pharmaceuticals, Inc. reported revenue of $2.5M (down 35.2% YoY) for Q3 FY2023, with a net profit of $-1.8M (down 1191.9% YoY) (-70.8% margin). Cost of goods sold was $819.0K, operating expenses totaled $2.4M.
Key Financial Metrics
| Total Revenue | $2.5M |
|---|---|
| Net Profit | $-1.8M |
| Gross Margin | 67.0% |
| Operating Margin | -28.1% |
| Report Period | Q3 FY2023 |
NovaBay Pharmaceuticals, Inc. Annual Revenue by Year
NovaBay Pharmaceuticals, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $9.8M).
| Year | Annual Revenue |
|---|---|
| 2024 | $9.8M |
| 2023 | $10.5M |
| 2022 | $14.4M |
NovaBay Pharmaceuticals, Inc. Quarterly Revenue & Net Profit History
NovaBay Pharmaceuticals, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2024 | $4.8M | +126.1% | $-1.2M | -25.5% |
| Q3 FY2024 | $0 | — | $-1.2M | N/A |
| Q2 FY2024 | $2.4M | -32.1% | $-1.6M | -66.0% |
| Q1 FY2024 | $2.6M | +12.5% | $-3.2M | -122.2% |
| Q4 FY2023 | $2.1M | -42.3% | $-4.1M | -195.5% |
| Q3 FY2023 | $2.5M | -35.2% | $-1.8M | -70.8% |
| Q2 FY2023 | $3.5M | -3.5% | $-2.0M | -57.6% |
| Q1 FY2023 | $2.3M | -28.5% | $-1.7M | -74.3% |
Income Statement
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.3M | $3.5M | $2.5M | $2.1M | $2.6M | $2.4M | $0 | $4.8M |
| YoY Growth | -28.5% | -3.5% | -35.2% | -42.3% | 12.5% | -32.1% | N/A | 126.1% |
Balance Sheet
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $14.8M | $16.0M | $12.9M | $9.0M | $5.4M | $3.9M | $3.9M | $3.4M |
| Liabilities | $5.9M | $7.4M | $5.8M | $5.7M | $5.2M | $4.5M | $2.8M | $3.6M |
| Equity | $8.9M | $8.6M | $7.0M | $3.3M | $160000 | $-617000 | $1.1M | $-129000 |
Cash Flow
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-1.2M | $-1.7M | $-646000 | $-592000 | $-2.0M | $-1.4M | $-2.4M | $-1.7M |